{Reference Type}: Journal Article
{Title}: Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.
{Author}: Regmi A;Aihara E;Christe ME;Varga G;Beyer TP;Ruan X;Beebe E;O'Farrell LS;Bellinger MA;Austin AK;Lin Y;Hu H;Konkol DL;Wojnicki S;Holland AK;Friedrich JL;Brown RA;Estelle AS;Badger HS;Gaidosh GS;Kooijman S;Rensen PCN;Coskun T;Thomas MK;Roell W;
{Journal}: Cell Metab
{Volume}: 36
{Issue}: 7
{Year}: 2024 Jul 2
{Factor}: 31.373
{DOI}: 10.1016/j.cmet.2024.05.010
{Abstract}: Tirzepatide, a glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor (GIPR/GLP-1R) agonist, has, in clinical trials, demonstrated greater reductions in glucose, body weight, and triglyceride levels compared with selective GLP-1R agonists in people with type 2 diabetes (T2D). However, cellular mechanisms by which GIPR agonism may contribute to these improved efficacy outcomes have not been fully defined. Using human adipocyte and mouse models, we investigated how long-acting GIPR agonists regulate fasted and fed adipocyte functions. In functional assays, GIPR agonism enhanced insulin signaling, augmented glucose uptake, and increased the conversion of glucose to glycerol in a cooperative manner with insulin; however, in the absence of insulin, GIPR agonists increased lipolysis. In diet-induced obese mice treated with a long-acting GIPR agonist, circulating triglyceride levels were reduced during oral lipid challenge, and lipoprotein-derived fatty acid uptake into adipose tissue was increased. Our findings support a model for long-acting GIPR agonists to modulate both fasted and fed adipose tissue function differentially by cooperating with insulin to augment glucose and lipid clearance in the fed state while enhancing lipid release when insulin levels are reduced in the fasted state.